Pay in 4 interest-free payments of $7.06 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
44, e13142
Professional liability considerations may differ from those associated with FDA-approved medications, and providers should maintain comprehensive documentation of treatment rationale and patient consent
TB-500 shares a similarly clean safety profile, though theoretical concerns exist regarding its pro-angiogenic and cell-migration properties in the context of existing tumors direct tumorigenic evidence is lacking, but researchers working with tumor models should note the potential interaction
The absence of published, large-scale human trials means that its use in clinical practice remains on the frontier of peptide medicine
)
